Department of Hematology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow, India.
PLoS One. 2018 Dec 27;13(12):e0209832. doi: 10.1371/journal.pone.0209832. eCollection 2018.
Bacterial and fungal infections still remain an important cause of mortality in patients with hematological malignancies and in recipients of hematopoietic stem cell transplants (HSCT) especially in developing countries like India. Granulocyte transfusions (GTX) from healthy donors may lead to early clearance of index infection and thus prevent mortality. The aim of the present study was to evaluate the efficacy of GTX in combating life-threatening infections and preventing mortality in patients of hematological disorders/recipients of HSCT with severe neutropenia. This study was a prospective, observational analysis of patients with different hematological disorders/recipients of HSCT, who received GTX from January 2014 to December 2017. All patients had an Absolute neutrophil Count (ANC) < 0.5 x 109/L and a life threatening sepsis defined by presence of hemodynamic instability/ impending septic shock/ continuous high fever despite the use of the highest line of antimicrobials. A total of 143 granulocyte collections were done for 66 infectious episodes (IEs) in 60 patients. Multidrug resistant organisms (MDROs) were observed in 47/66 IEs (71.2%) and fungal infections were seen in 9/66 IEs (13.6%). Resolution of index infection after GTX was seen in 45/66 IEs (68.2%), and the 30 day overall survival (OS) was 67.7%. OS was significantly higher in patients who received GTX within 7 days of neutropenic sepsis (p = 0.01). Patients with MDROs who received early GTX therapy had a better OS as compared to those who received late GTX (p = 0.02). GTX were well tolerated and only 6 patients' developed mild features of transfusion related acute lung injury (TRALI) which was managed conservatively, and 1 patient demonstrated hypocalcemic tetany. GTX may be of particular relevance in countries like India, where the incidence of infections is very high in neutropenic patients and there is an increasing emergence of MDROs.
细菌和真菌感染仍然是血液恶性肿瘤患者和造血干细胞移植(HSCT)受者死亡的重要原因,特别是在印度等发展中国家。来自健康供者的粒细胞输注(GTX)可能导致指数感染的早期清除,从而预防死亡。本研究的目的是评估 GTX 在对抗血液系统疾病患者/HSCT 受者严重中性粒细胞减少症的危及生命的感染和预防死亡方面的疗效。这项研究是对 2014 年 1 月至 2017 年 12 月接受 GTX 的不同血液系统疾病/HSCT 受者进行的前瞻性观察性分析。所有患者的绝对中性粒细胞计数(ANC)<0.5 x 109/L,且存在血流动力学不稳定/即将发生感染性休克/尽管使用了最高线的抗生素仍持续高热的危及生命的败血症。在 60 名患者的 66 次感染发作(IE)中进行了 143 次粒细胞采集。在 66 次 IE 中观察到 47/66 次(71.2%)出现多重耐药菌(MDROs)和 9/66 次(13.6%)出现真菌感染。GTX 后指数感染得到缓解的有 45/66 次 IE(68.2%),30 天总生存率(OS)为 67.7%。在中性粒细胞减少性败血症发生后 7 天内接受 GTX 的患者 OS 显著更高(p = 0.01)。早期接受 GTX 治疗的 MDROs 患者的 OS 明显优于晚期接受 GTX 治疗的患者(p = 0.02)。GTX 耐受性良好,仅 6 例患者出现轻微的输血相关急性肺损伤(TRALI)表现,经保守治疗,1 例患者出现低钙性抽搐。GTX 在印度等感染率在中性粒细胞减少症患者中非常高且 MDROs 不断出现的国家可能具有特殊意义。